Literature DB >> 34264440

Ensemble learning application to discover new trypanothione synthetase inhibitors.

Juan I Alice1,2, Carolina L Bellera1,2, Diego Benítez3, Marcelo A Comini3, Pablo R Duchowicz4, Alan Talevi5,6.   

Abstract

Trypanosomatid-caused diseases are among the neglected infectious diseases with the highest disease burden, affecting about 27 million people worldwide and, in particular, socio-economically vulnerable populations. Trypanothione synthetase (TryS) is considered one of the most attractive drug targets within the thiol-polyamine metabolism of typanosomatids, being unique, essential and druggable. Here, we have compiled a dataset of 401 T. brucei TryS inhibitors that includes compounds with inhibitory data reported in the literature, but also in-house acquired data. QSAR classifiers were derived and validated from such dataset, using publicly available and open-source software, thus assuring the portability of the obtained models. The performance and robustness of the resulting models were substantially improved through ensemble learning. The performance of the individual models and the model ensembles was further assessed through retrospective virtual screening campaigns. At last, as an application example, the chosen model-ensemble has been applied in a prospective virtual screening campaign on DrugBank 5.1.6 compound library. All the in-house scripts used in this study are available on request, whereas the dataset has been included as supplementary material.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Chagas disease; Ensemble learning; Machine learning; QSAR; Trypanosoma cruzi; Trypanothione synthetase

Mesh:

Substances:

Year:  2021        PMID: 34264440     DOI: 10.1007/s11030-021-10265-9

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  32 in total

1.  Genetic and chemical analyses reveal that trypanothione synthetase but not glutathionylspermidine synthetase is essential for Leishmania infantum.

Authors:  André F Sousa; Ana G Gomes-Alves; Diego Benítez; Marcelo A Comini; Leopold Flohé; Timo Jaeger; Joana Passos; Friedrich Stuhlmann; Ana M Tomás; Helena Castro
Journal:  Free Radic Biol Med       Date:  2014-05-20       Impact factor: 7.376

2.  Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods.

Authors:  Catalina Muñoz; Inés Zulantay; Werner Apt; Sylvia Ortiz; Alejandro G Schijman; Margarita Bisio; Valentina Ferrada; Cinthya Herrera; Gabriela Martínez; Aldo Solari
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

3.  Validation of Trypanosoma brucei trypanothione synthetase as drug target.

Authors:  Marcelo A Comini; Sergio A Guerrero; Simon Haile; Ulrich Menge; Heinrich Lünsdorf; Leopold Flohé
Journal:  Free Radic Biol Med       Date:  2004-05-15       Impact factor: 7.376

4.  The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing strategies.

Authors:  Alan Talevi; Carolina Carrillo; Marcelo A Comini
Journal:  Curr Med Chem       Date:  2018-09-26       Impact factor: 4.530

5.  Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids.

Authors:  A H Fairlamb; P Blackburn; P Ulrich; B T Chait; A Cerami
Journal:  Science       Date:  1985-03-22       Impact factor: 47.728

Review 6.  Metabolism and functions of trypanothione in the Kinetoplastida.

Authors:  A H Fairlamb; A Cerami
Journal:  Annu Rev Microbiol       Date:  1992       Impact factor: 15.500

Review 7.  Trypanosomatid parasites causing neglected diseases.

Authors:  K Nussbaum; J Honek; C M C v C Cadmus; T Efferth
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

8.  The BENEFIT Trial: Where Do We Go from Here?

Authors:  Bernard Pecoul; Carolina Batista; Eric Stobbaerts; Isabella Ribeiro; Rafael Vilasanjuan; Joaquim Gascon; Maria Jesus Pinazo; Silvia Moriana; Silvia Gold; Ana Pereiro; Miriam Navarro; Faustino Torrico; Maria Elena Bottazzi; Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2016-02-25

Review 9.  Chagas disease research and development: Is there light at the end of the tunnel?

Authors:  Eric Chatelain
Journal:  Comput Struct Biotechnol J       Date:  2016-12-14       Impact factor: 7.271

10.  Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.

Authors:  Alejandro M Hasslocher-Moreno; Roberto M Saraiva; Luiz H C Sangenis; Sergio S Xavier; Andrea S de Sousa; Andrea R Costa; Marcelo T de Holanda; Henrique H Veloso; Fernanda S N S Mendes; Filipe A C Costa; Marcio N Boia; Pedro E A A Brasil; Fernanda M Carneiro; Gilberto M Sperandio da Silva; Mauro F F Mediano
Journal:  EClinicalMedicine       Date:  2020-12-23
View more
  1 in total

1.  Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening.

Authors:  Diego Benítez; Jaime Franco; Florencia Sardi; Alejandro Leyva; Rosario Durán; Gahee Choi; Gyongseon Yang; Taehee Kim; Namyoul Kim; Jinyeong Heo; Kideok Kim; Honggun Lee; Inhee Choi; Constantin Radu; David Shum; Joo Hwan No; Marcelo A Comini
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.